Clinicians and scientists have long questioned whether the immune system has a role in destroying cancerous tissue. Studies performed in animal models have, however, recently revealed that the immune system can, at least in principle, effectively control tumours. In parallel with these findings, a large body of evidence indicates that although the immune system has the capacity to control tumours, there are also regulatory mechanisms that subdue these responses. A major challenge of tumour immunotherapy, therefore, is to find ways of disabling these regulatory functions while restoring or priming any immune responses that are protective.
Introduction
Whether the immune system can be harnessed for the purposes of effective tumour immunotherapy is still uncertain. The types of immune cells and functions optimal for controlling tumour growth in vivo have not been definitively identified. In addition, it is clear that tumours are adept at tolerizing the immune system, propagating a variety of negative influences that serve to dampen down effective antitumour immunity. The last decade has seen a resurgence of interest in mechanisms of dominant tolerance mediated by the subpopulation termed regulatory T cells (Tregs). These cells, defined by the expression of the CD4 antigen and the forkhead transcription factor, Foxp3, apparently play roles in autoreactivity, allergy and infection, keeping both adaptive and innate immune responses in check and limiting autoimmunity and immunopathology (Sakaguchi, 2004) .
A key role for Foxp3 in Treg function was revealed following genetic characterization of the scurfy mouse (Brunkow et al., 2001) . Scurfy mice develop fatal lymphoproliferative disease, caused by a mutated foxp3 gene resulting in a truncated and dysfunctional form of the transcription factor. Confirmation of the association between Foxp3 and Treg function was obtained when it was shown that adoptive transfer of CD4 þ CD25 þ cells from wild-type mice suppressed the disease in scurfy recipients (Fontenot et al., 2003) . Studies of patients with IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome) followed those of Scurfy mice as it was observed that IPEX sufferers exhibited symptoms similar to those of Scurfy mice. Mutations in foxp3 were indeed found in afflicted individuals thereby confirming the important role Foxp3 plays in immune regulation (Wildin et al., 2001) .
The suppressive effect of Tregs on immune responses to tumours is widely documented. Numerous studies in mouse models indicate that removal of Tregs promotes rejection of tumour cell lines or can even prevent their development in vivo in either cancer-prone mice or after treatment with chemical carcinogens. In the majority of studies, Tregs appear more frequent in peripheral blood lymphocytes from patients with cancer than healthy controls (reviewed in ). Their depletion from peripheral blood lymphocytes in vitro uncovers T-cell responses to tumour antigens and, in vivo, it can enhance immune responses generated following vaccination (Dannull et al., 2005) . There are also reports that high Treg frequencies correlate with more advanced disease, implying that they influence cancer progression (reviewed in ). Overall, these studies are compelling. They imply that a greater knowledge of the types of immune cells and functions inhibited by Tregs, together with insights into why and how Tregs become so heavily involved in antitumour responses, holds the key to deciphering whether the immune system can be harnessed for the control of cancer.
Tregs: a conspicuous presence within tumours
Tregs are evidently enriched within some tumours. Identification of Foxp3-expressing cells by either immunofluorescence or flow cytometry has revealed an enrichment of these cells in ovarian carcinoma, breast carcinoma and lymphoma (Curiel et al., 2004; Roncador et al., 2005; Leong et al., 2006) . Likewise, flow cytometric analyses of Foxp3-expressing cells in carcinogeninduced tumours in mice have revealed a significant enrichment of these cells . Overall Tregs are readily detectable in tumours and may even increase in number as disease progresses (Ichihara et al., 2003; Curiel et al., 2004) . The picture that emerges is of Tregs gradually assuming control of the immune environment within a tumour, shutting off antitumour effector mechanisms and favouring progression.
What do they recognize and where do they come from? It appears that Tregs can develop either in the thymus, the so-called naturally occurring Tregs (nTregs), or in the periphery as CD4 þ CD25 À cells acquire Foxp3 expression and suppressor activity. The latter population has been named induced Tregs (iTregs). Either or both of these populations may become enriched within tumours, through a variety of mechanisms facilitated by conditions within the tumour microenvironment. Cytokines and chemokines produced within tumours may preferentially support proliferation, migration, retention and/or survival of Tregs when compared with other tumour-infiltrating leukocytes. A detailed characterization of the cytokine and chemokine profile of different tumours in association with a comprehensive analysis of chemokine receptors expressed by Tregs may help shed light on some of these processes. Certainly evidence already exists to support a role for TGFb in promoting proliferation of Tregs in tumours, and for the chemokine CCL22 in attracting Tregs into human ovarian tumours (Curiel et al., 2004; Ghiringhelli et al., 2005b; Bui et al., 2006; Valzasina et al., 2006; Liu et al., 2007; Zhou and Levitsky, 2007) .
Mechanisms of action
Tregs may exert their suppressive effects using one or more of a number of different mechanisms including production of immunosuppressive cytokines, delivery of inhibitory signals following cell-cell contact, delivery of immunosuppressive molecules through gap junctions, expression of cell surface endonucleosidases and direct killing of conventional T cells using perforin or granzyme-dependent mechanisms (Asseman et al., 1999; Takahashi et al., 2000; Gondek et al., 2005; Bopp et al., 2007; Deaglio et al., 2007) . In addition, results obtained using two-photon microscopy to follow the behaviour of the cells in lymph nodes indicate that Tregs interact with DCs preventing them from forming stable contacts with conventional T cells (Tadokoro et al., 2006; Tang et al., 2006) . Given that, as listed above, many mechanisms may account for their inhibitory activity, it is possible that their precise mechanism of action depends on their anatomical location, the type of immune cell that is being suppressed and on the stimulation conditions. Thus, the way in which Tregs inhibit priming of conventional T cells in lymphoid tissue may be distinct from mechanisms utilized for the purposes of suppressing effector T cells in peripheral tissues including tumours.
Selection of naturally occurring Tregs
In a series of experiments using transgenic mice, nTregs have been shown to be more resistant to negative selection than other T cells. Recent results indicate that Tregs are specifically selected by tissue-specific auto-epitopes expressed on medullary thymic epithelial cells at levels that usually mediate clonal deletion (Aschenbrenner et al., 2007) . Thus, it appears that, during thymic selection, nTregs have TCR affinities just too low for deletion and resist negative selection, and are either instructed to become Tregs (and express FoxP3) or they become enriched by elimination of T cells that fail to upregulate FoxP3. In any case, it was concluded that Tregs are the circulating peripheral T cells with highest affinities for self (Jordan et al., 2001; Apostolou et al., 2002) . This well accepted dogma was recently challenged by two groups who sequenced hundreds of TCRs from peripheral and thymic Tregs or naive T cells, and demonstrated that: (a) the extent of diversity in the repertoire of CD25 þ and CD25-T cells was comparable (Hsieh et al., 2004; Pacholczyk et al., 2007) , and that the repertoires overlapped significantly (Pacholczyk et al., 2007) . Moreover, (b) high affinity autoreactive T cells were rare in both populations and the self-peptide that selected the Tregs in the thymus was not responsible for activating their suppressor function in the periphery (Pacholczyk et al., 2007) .
Tumour antigens recognized by effector lymphocytes have been clearly classified into several categories. Categories of antigens that are recognized by the immune system as foreign and are therefore tumourspecific comprise (1) mutated genes that arise as a consequence of gene arrangements or point mutations, (2) viral oncogenes and (3) molecules that display abnormal post-translational modifications such as underglycosylated mucin, MUC-1. In addition to these foreign antigens there are several types of self-antigens that are shared by the body and the tumour: (4) cancertestis antigens, which are proteins encoded by genes that are normally expressed only in male germ cells. Tumor cells show widespread abnormalities of gene expression, including the activation of these genes. (5) Differentiation antigens encoded by genes that are only expressed in particular types of tissue such as the differentiation antigens expressed in melanocytes and melanoma cells and which are involved in melanin production. (6) The last category is comprised of antigens that are strongly overexpressed in tumor cells compared with their normal counterparts. An example is HER-2/neu (also known as c-Erb-2), which is a receptor tyrosine kinase homologous to the epidermal growth factor receptor. Responses to all categories of antigens have been observed among conventional CD4 þ and/or CD8 þ effector cells. However, for the tumour immunologist developing vaccines and therapies, the specificities of Tregs involved in antitumour immune responses remain a major question. Do they mostly recognize self-antigens and therefore also cancer-testis antigens? Wang et al. (2004) mapped the fine specificity of tumour-infiltrating CD4 þ T cells by screening a cDNA library made from melanoma RNA. One of the epitopes recognized by Treg clones was LAGE-1, an NY-ESO homolog and member of the large cancer-testic antigen family.
Whether Tregs that are involved in antitumour responses recognize the same self-peptides that are responsible for their thymic selection is unknown. It is possible that NY-ESO is expressed in mTECs, thereby driving the specific selection of Tregs. Other tumour antigens expressed promiscuously in mTECs are the melanocyte differentiation antigens gp100 and Tyrosinase (Derbinski et al., 2001) . Such expression could therefore represent one mechanism for selection of tumour antigen-specific Tregs. Only further analysis of the specificities of those involved in immune responses to tumours will clarify this issue.
Non-regulatory autoreactive T cells are readily observed in the peripheral T-cell pool of healthy individuals, and it is thought that these autoreactive T cells can be, although of low affinity for self-antigens, mediators of tumour immunosurveillance. Whether this repertoire has been positively selected by the immune system to protect against tumours needs further investigation. Thus, low affinity autoreactive T cells could form an important part of the adaptive antitumour response, possibly in addition to non-autoreactive crossreactive T cells. Such an argument would predict that cancer exerts natural selection on the immune system, that is, before the end of the reproductive age such as cancers occurring in childhood. If naturally occurring autoreactive T cells were able to combat tumours and therefore become activated by the tumour, then autoreactivity could arise as a consequence of antitumour activity. Indeed there are several examples of natural effective antitumour responses accompanied by autoimmune symptoms. Firstly, autoimmune paraneoplastic neurological disorders (PND) apparently result from an antitumour response against neuronal antigens that are aberrantly expressed in cancer cells. If these provoke an autoimmune response, the tumour prognosis is sometimes strikingly better than in tumour patients with no PND (Darnell and Posner, 2003) . Secondly, vitiligo is an autoimmune skin-depigmenting disorder, with loss of epidermal melanocytes (Yee et al., 2000) . It is frequently observed in melanoma patients and is associated with a good prognosis. If it is true that autoreactive T cells have been positively selected to fight tumours, and Tregs are the circulating T cells with highest affinity for self, then the question arises why would a T-cell repertoire evolve where the Tregs have an inbuilt advantage over the effector T cells? Perhaps, as suggested by Pacholczyk et al. (2007) , Tregs do not have a higher affinity for self-antigen than conventional autoreactive cells, but merely a numerical advantage during the later stages of tumour development. The current mind-set is that autoreactive T cells are selected because their affinities are below a rather permissive threshold for negative selection so that incomplete negative selection can maximize the number of T cells reactive to foreign antigens. If so, Tregs would be needed to keep these autoreactive T cells in check, consequently limiting the scope for antitumour responses.
As mentioned above, many more studies of the specificities of the Tregs involved in antitumour responses are warranted so that their role in tumour development can be fully understood. What is clear, however, is that nTregs, which may display antigenspecificities distinct from those of conventional tumourspecific effector cells, are not the only CD4
þ Foxp3 þ cells present in the tumour microenvironment.
Inducible Tregs
Several studies have revealed that Tregs can be induced (iTregs) from conventional T cells in response to progressing tumours (Ghiringhelli et al., 2005b; Beyer et al., 2006; Valzasina et al., 2006; Liu et al., 2007) . The conditions that facilitate this process are as yet ill defined, although it is clear that certain cytokines can drive differentiation of naive T cells into Th1, Th2, Th17 or Treg cells both in vitro and in vivo. Experiments performed in vitro indicate that cytokines such as TGF-b and IL-2 are essential for generation of iTreg (Chen et al., 2003; Davidson et al., 2007; Zheng et al., 2007) while others such as IFNg may also facilitate the process. It has been reported that IFNg can promote conversion of conventional T cells into Tregs in vitro (Wang et al., 2006) , and that Tregs are reduced in number at sites of autoreactivity in IFNg-deficient mice (Kelchtermans et al., 2005) . For this reason it has been suggested that IFNg, produced as part of an inflammatory response, serves to trigger regulatory mechanisms either by promoting priming and expansion of nTregs or facilitating development of iTreg. We recently reported significantly reduced infiltration by Tregs in MCAinduced tumours in IFNg-deficient mice . This may be because of IFN-g, or perhaps other cytokines that it evokes, facilitating conversion of conventional T cells into Tregs in vivo.
Other cytokines that may have a significant effect on the composition of the tumour-infiltrating lymphocyte pool are TGFb and IL-6, which have both been found in abundance in a variety of tumours, particularly advanced tumours (Asselin-Paturel et al., 1998; Conrad et al., 1999; Kryczek et al., 2000) . IL-6 recently emerged as a major player governing the differentiation of naive T cells. In mice, the combination of IL-6 and TGFb promotes differentiation of naive T cells into Th17 cells whereas, in the absence of IL-6, TGFb promotes differentiation of naive T cells into Tregs (Bettelli et al., 2006) . In the case of tumours however, it was reported recently that the number of Th17 cells and Tregs was gradually and synchronously increased in the tumour, indicating that its microenvironment can support both cell types and that IL-6 does not act as a switch favouring Th17 cells at the expense of Tregs, at least in vivo (Kryczek et al., 2007) . Indeed, in a model of autoimmunity, TGFb produced by Tregs was shown to support Th17 cell differentiation (Veldhoen et al., 2006) . Both of these cell types may interfere with tumour rejection; while Tregs inhibit protective antitumour effector cells, IL-17 produced by Th17 cells, may facilitate angiogenesis (Numasaki et al., 2003) and attract tumour promoting inflammatory cells, thereby contributing to tumour progression.
Another cytokine linked to the Th17 differentiation pathway is IL-23; while playing a key role in differentiation of Th17 cells in humans, it is important mainly for the expansion of Th17 cells in mice (Wilson et al., 2007) . Though its impact on Treg activity is undefined, there is clearly a lower incidence of carcinogen-induced tumours in mice genetically deficient in IL-23 or treated with blocking antibodies (Langowski et al., 2006) . It is also highly expressed by human tumours and may prove to be a useful target for antitumour immunotherapy.
The most recently discovered member of the IL-2 cytokine family is IL-21, which also impacts on Treg activity Nurieva et al., 2007; Peluso et al., 2007; . Produced by activated T cells, it is known to be involved in Th2 responses and also to promote the activity of CD8 þ T cells (Zeng et al., 2005) and NK cells (Wang et al., 2003) . IL-21 drives development of mouse Th17 cells in an autocrine fashion and upregulates expression of the IL-23R on CD4 þ T cells (Nurieva et al., 2007) . Although IL-21 and IL-2 share some activities, their effects on Tregs are distinct. Unlike IL-2, IL-21 is not required for the proliferation or the immunosuppressive effects of Tregs. Indeed, it has been reported that IL-21 can both suppress Foxp3 expression and subvert the activity of Tregs by rendering CD4 þ CD25 À cells resistant to their suppressive effects (Peluso et al., 2007) .
The studies described above indicate that the cytokine milieu is likely to profoundly influence the impact of both nTreg and iTreg on the immune response to the tumours. Cyto-and chemokines present in the tumour and its draining lymph nodes may influence proliferation, migration and retention of the cells at sites of antitumour activity-whether directly or indirectly through effects on other cytokines and chemokines. In addition, through effects on conventional T cells, they may determine the contribution of iTregs to the overall immune response. It is not yet known whether iTregs differentiate only from naive T cells or whether already activated T cells, perhaps present within the tumour microenvironment, can also be converted into Tregs. One candidate for the conversion of tumour-infiltrating T cells into Tregs is Indoleamine 2,3-dioxygenase, an immunosuppressive agent, often produced by tumour cells (Curti et al., 2007) .
The nature of the immune response to the tumour is also likely to change as it progresses, when shifting cytokine profiles may alter the balance between one T-cell type and the other. Overall, evidence from mouse models suggest that Th1 responses, characterized by IFNg and IL-12 production and robust CTL and NK cell activity, are key features of a successful antitumour immune response (Figure 1 and reviewed in (Smyth et al., 2006a) ). There is abundant evidence indicating that the activity of these cells is enhanced by Treg depletion (reviewed in ). As gd T cells can also contribute to control of tumours (Girardi et al., 2001) , their susceptibility to the suppressive effects of Tregs also demands to be tested. Whereas the IL-12-IFNg axis is associated with tumour elimination, the IL-23/IL-21-IL17 axis is associated with tumour progression (Figure 1 ), characterized by a predominance of antigen non-specific inflammatory cells and production of pro-inflammatory cytokines such as TNFa and IL-6.
As mentioned above, tumours are less frequent in mice lacking IL-23, implying that it promotes their development. Several mechanisms may underlie its pro-tumoral actions. Not only does IL-23 promote inflammatory responses that may facilitate tumour progression: it can also inhibit infiltration of CD8 þ T cells into tumours (Langowski et al., 2006) , as well as antagonizing IL-12 and IFNg, which, as described above, are known to activate NK cells, Th1 cells and cytotoxic T cells to control and eliminate tumour cells. As IL-23 is highly expressed in many human tumours (Langowski et al., 2006) , it may prove a key target for altering the antitumour immune climate, as its neutralization might shut down pro-tumoral inflammatory processes while enhancing the antitumour activity of antigen-specific CD8 þ T cells. Paradoxically, one way of reducing IL-23 production may be through Tregs; many recent studies imply that, by suppressing these inflammatory responses, they actually hinder the progression of some tumours. For example, adoptive transfer of CD4 þ CD25 þ T cells hinders development of both Helico-bacter hepaticus-associated tumours in infected Rag-knockout mice (Erdman et al., 2003) and of intestinal adenomas in ApcMin/ þ mice, an effect that correlated with a decrease in pro-inflammatory cytokines and Cox2 expression (Erdman et al., 2005) . Furthermore, it has been shown that inhibition of Cox2 leads to a decrease in Treg activity with a concomitant increase in production of pro-inflammatory cytokines and in vivo growth of Lewis Lung carcinoma in mice (Sharma et al., 2005) . Collectively, these data indicate that the net effect of Treg activity on tumour progression depends on the nature of the immune response to the tumour: where it is predominantly Th1-type, the inhibitory effects of Tregs compromise tumour elimination. By contrast, where inflammatory cells and cytokines are in the ascendant, Tregs may beneficially dampen down those responses that actually otherwise promote tumour growth (see Figure 1 ).
Other cell types than effector ab T cells have an effect on tumour growth-this effect can either be beneficial for the tumour or the host, and cell types include B cell responses, NK and NKT cells, macrophages, dendritic cells, neutrophils and eosinophils (Table 1) . Although for a majority of these cells an inhibitory effect of regulatory T cells has been observed for model antigens and other diseases, there are very few studies directly relating to tumours in this field (Table 1) . The table summarizes the different immunological cell types (column 1) and their mode of action on modulating tumour growth (column 2). Some cells and their factors promote tumour growth (bold) and some inhibit tumour growth (non bold). The effect of regulatory T cells on these cell types is described in column 3 with references relating to regulatory T cells in column 4.
Overall the data discussed above imply that the outcome of the relationship between a developing tumour and the immune system depends on the combined interactions between many different cell types, and may evolve as the tumour progresses. The precise nature of an effective antitumour immune response remains especially difficult to define in patients with cancer, as any observed immune responses have manifestly failed to control the tumour. Detailed knowledge of how Tregs impact on different types of immune responses, and of cytokine networks that influence the types of T cells involved in an antitumour response, should, however, reveal ways through which those cells that promote tumour growth can be subdued and perhaps even converted into protective antitumour effector cells.
